Seliciclib (roscovitine or CYC202) is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase or state within the cell cycle of treated cells. Seliciclib is being developed by Cyclacel.This is a phase II, dose ranging, multicenter, randomized, double-blind, placebo-controlled study. This study involved 36 Cystic Fibrosis patients: 24 treated and 12 controls.

Property Value
dbo:abstract
  • Seliciclib (roscovitine or CYC202) is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase or state within the cell cycle of treated cells. Seliciclib is being developed by Cyclacel.This is a phase II, dose ranging, multicenter, randomized, double-blind, placebo-controlled study. The aim of this study is to assess the safety of increasing doses of roscovitine administered orally for 4 cycles of 4 consecutive days (treatment "on") separated by a 3 days treatment free period (treatment "off") in adult CF subjects with Cystic Fibrosis carrying 2 Cystic Fibrosis causing mutations with at least one F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa. This study involved 36 Cystic Fibrosis patients: 24 treated and 12 controls. Seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), Cushing's disease, leukemia, HIV infection, Parkinson’s disease, herpes simplex infection, cystic fibrosis and the mechanisms of chronic inflammation disorders. Seliciclib is a 2,6,9-substituted purine analog. Its structure in complex with CDK2 was determined in 1996. Seliciclib inhibits CDK2/E, CDK2/A, CDK7 and CDK9. (en)
dbo:alternativeName
  • Roscovitine; CYC202 (en)
dbo:iupacName
  • 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine (en)
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExtracted
  • 2019-08-19 07:09:59Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 4769591 (xsd:integer)
dbo:wikiPageLength
  • 10608 (xsd:integer)
dbo:wikiPageModified
  • 2019-08-19 07:09:55Z (xsd:date)
dbo:wikiPageOutDegree
  • 41 (xsd:integer)
dbo:wikiPageRevisionID
  • 911495300 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Seliciclib (roscovitine or CYC202) is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase or state within the cell cycle of treated cells. Seliciclib is being developed by Cyclacel.This is a phase II, dose ranging, multicenter, randomized, double-blind, placebo-controlled study. This study involved 36 Cystic Fibrosis patients: 24 treated and 12 controls. (en)
rdfs:label
  • Seliciclib (en)
owl:sameAs
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is foaf:primaryTopic of